admin – Page 220 – Get News Story

CAR-T Pipeline Expands as 180+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “CAR T-Cell Therapy Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the CAR T-Cell Therapy pipeline landscape. It covers the CAR T-Cell Therapy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR T-Cell Therapy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the CAR T-Cell Therapy Pipeline? @ https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight

Key Takeaways from the CAR T-Cell Therapy Pipeline Report

On June 01, 2026- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company initiated a phase 2 study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.
On May 27, 2026- Novartis Pharmaceuticals announced a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.
On May 26, 2026- Abramson Cancer Center at Penn Medicine conducted a phase II study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
On May 22, 2026- AstraZeneca initiated a Phase I/II study will evaluate the safety, tolerability, antitumour activity, cellular kinetics, pharmacodynamics, and immunogenicity of AZD5851 in adult participants with GPC3+ advanced/recurrent HCC, where at least one line of prior therapy has failed/or was intolerable, or participant/investigator decision.
DelveInsight’s CAR T-Cell Therapy Pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for CAR T-Cell Therapy treatment.
The leading CAR T-Cell Therapy Companies such as Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Caribou Biosciences, Atara Bio therapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals and others.
Promising CAR T-Cell Therapy Therapies such as Itacitinib, Cyclophosphamide, Fludarabine, WU-CART-007, Cevostamab, JNJ-68284528, Lenalidomide, Daratumumab, KYV-101, Epcoritamab, and others.

Want to know which companies are leading innovation in CAR T-Cell Therapy? @ CAR T-Cell Therapy Clinical Trials Assessment

The CAR T-Cell Therapy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The CAR T-Cell Therapy Pipeline Report also highlights the unmet needs with respect to the CAR T-Cell Therapy.

CAR T-Cell Therapy Overview

CAR-T cell therapy represents a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer. This cutting-edge therapy involves a meticulous process where a patient’s own T cells, a vital component of the immune system responsible for identifying and eliminating foreign invaders, are genetically engineered to specifically target and destroy cancer cells. The process begins by extracting T cells from the patient’s blood through a process called leukapheresis. Once isolated, these T cells undergo genetic modification in the laboratory. Specifically, scientists introduce a gene encoding a chimeric antigen receptor (CAR) into the T cells. This CAR is designed to recognize and bind to a specific protein expressed on the surface of cancer cells. This customization ensures that the engineered T cells can specifically target and attack cancerous cells while sparing healthy cells.

CAR T-Cell Therapy Emerging Drugs Profile

Descartes-08: Cartesian Therapeutics

Descartes-08 is an autologous anti-B cell maturation antigen (BCMA) mRNA CAR-T. Compared to conventional DNA-based CAR T-cell therapies, mRNA CAR-T is designed not to require preconditioning chemotherapy, has been observed to have predictable and controllable pharmacokinetics, and is designed to avoid the risk of genomic integration. Descartes-08 has been granted Orphan Drug Designation by the US FDA for the treatment of MG, a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Currently, the drug is in Phase II stage of clinical trial for the treatment of autoimmune disorders.

KYV-101: Kyverna Therapeutics

KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase 1 trial in oncology. Results were published by the NIH in Nature Medicine3. KYV-101 is currently being evaluated in sponsored, open-label, Phase 1/2 trials of KYV-101 in patients with lupus nephritis, an autoimmune disease in which more than half of patients do not achieve a complete response to current therapies and are at risk of developing kidney failure. Additionally, FDA’s IND clearance has been obtained for Phase 2 trials of KYV-101 for multiple sclerosis and myasthenia gravis, and a Phase I/II trial for systemic sclerosis.

TX200: Sangamo Therapeutics

TX200 is composed of the patient’s own (autologous) regulatory T cells (Tregs) engineered to express a chimeric antigen receptor (CAR) designed to recognize the HLA-A2 protein present on a transplanted kidney and bind to it. TX200 is in development for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. It is in Phase I/II stage of its clinical trial.

ALLO-605: Allogene Therapeutics

ALLO-605, a next-generation AlloCAR T™ known as a TurboCAR™, is an investigational product that targets the B-cell maturation antigen (BCMA) for the treatment of patients with relapsed/refractory multiple myeloma and other BCMA-positive malignancies. This study uses ALLO-647, Allogene’s proprietary monoclonal antibody (mAb), as a part of its differentiated lymphodepletion regimen. ALLO-605 incorporates Allogene’s proprietary TurboCAR technology, which allows for cytokine activation signaling to be engineered selectively into CAR T cells. In June 2021, ALLO-605 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed/refractory multiple myeloma. The Phase 1 study evaluating ALLO-605 is underway. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Multiple Myeloma.

ATA3219: Atara Biotherapeutics

ATA3219 combines the natural biology of unedited T cells with the benefits of an allogeneic therapy. It consists of allogeneic Epstein-Barr virus (EBV)-sensitized T cells that express a CD19 CAR construct for the treatment of CD19+ relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin’s lymphoma and B-cell mediated autoimmune diseases including systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]). ATA3219 has been optimized to offer a potential best-in-class profile, featuring off-the-shelf availability. Currently, the drug is in Phase I stage of its clinical trial.

CB-010: Caribou Biosciences

CB-010 is an allogeneic anti-CD19 CAR-T cell therapy for the treatment of patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). CB-010 is the first allogeneic CAR-T cell therapy, to our knowledge, in a clinical trial with a PD-1 knockout, a genome-editing strategy designed to improve antitumor activity by limiting premature CAR-T cell exhaustion. CB-010 is being evaluated in the ongoing, open-label, multicenter ANTLER Phase I clinical trial in adults with r/r B-NHL.

If you’re tracking ongoing CAR T-Cell Therapy Clinical trials @ CAR T-Cell Therapy Treatment Drugs

The CAR T-Cell Therapy Pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of CAR T-Cell Therapy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR T-Cell Therapy Treatment.
CAR T-Cell Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
CAR T-Cell Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR T-Cell Therapy market.

CAR T-Cell Therapy Companies

Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Caribou Biosciences, Atara Bio therapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals and others.

CAR T-Cell Therapy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

Oral
Intravenous
Subcutaneous
Parenteral
Topical

CAR T-Cell Therapy Products have been categorized under various Molecule types such as,

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

From emerging drug candidates to competitive intelligence, the CAR T-Cell Therapy Pipeline Report @ CAR T-Cell Therapy Market Drivers and Barriers, and Future Perspectives

Scope of the CAR T-Cell Therapy Pipeline Report

Coverage- Global
CAR T-Cell Therapy Companies- Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Caribou Biosciences, Atara Bio therapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals and others.
CAR T-Cell Therapy Therapies- Itacitinib, Cyclophosphamide, Fludarabine, WU-CART-007, Cevostamab, JNJ-68284528, Lenalidomide, Daratumumab, KYV-101, Epcoritamab, and others.
CAR T-Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
CAR T-Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the CAR T-Cell Therapy Treatment landscape in this detailed analysis @ CAR T-Cell Therapy Emerging Drugs and Major Players

Table of Contents

Introduction
Executive Summary
CAR-T: Overview
Pipeline Therapeutics
Therapeutics Assessment
CAR-T– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
Descartes-08: Cartesian Therapeutics
Early Stage Products (Phase I)
ATA3219: Atara Biotherapeutics
Preclinical and Discovery Stage Products
Inactive Products
CAR-T Key Companies
CAR-T Key Products
CAR-T- Unmet Needs
CAR-T- Market Drivers and Barriers
CAR-T- Future Perspectives and Conclusion
CAR-T Analyst Views
CAR-T Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/car-t-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR-T Pipeline Expands as 180+ Companies Driving Innovation in the Therapeutics | DelveInsight

Atopic Dermatitis Pipeline Shows Potential with Active Contributions from 100+ Key Companies | DelveInsight

DelveInsight’s “Atopic Dermatitis Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Dermatitis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Atopic Dermatitis Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight

Key Takeaways from the Atopic Dermatitis Pipeline Report

On June 02, 2026- Apollo Therapeutics Ltd initiated a phase 2b study will enroll both treatment-naive participants and those with an inadequate response to previous biologic therapy.
On May 27, 2026- Inmagene LLC announced a phase 2b study to assess the efficacy and safety profile of various dose regimens of IMG-007 in adult participants with moderate-to-severe active atopic dermatitis (AD) up to 48 weeks.
On May 26, 2026- Apogee Therapeutics Inc. conducted a Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948).
On May 22, 2026- Incyte Corporation announced a phase 3b study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
On May 22, 2026- UCB Biopharma SRL initiated a study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
On May 22, 2026- Eli Lilly and Company conducted a phase 4 study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
DelveInsight’s Atopic Dermatitis Pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Atopic Dermatitis treatment.
The leading Atopic Dermatitis Companies such as Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.
Promising Atopic Dermatitis Therapies such as Dupilumab, betamethasone valerate, GW842470X cream, LAS 41002, Hydrocortisone Ointment, Clobetasol Ointment, TAVO101, Apremilast, HY209GEL, and others.

Want to know which companies are leading innovation in Atopic Dermatitis? Dive into the full pipeline insights @ Atopic Dermatitis Clinical Trials Assessment

The Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Atopic Dermatitis Pipeline Report also highlights the unmet needs with respect to the Atopic Dermatitis.

Atopic Dermatitis Overview

Atopic Dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies. It is the most common chronic skin disease in children.

Atopic Dermatitis Emerging Drugs Profile

ICP-332: Innocare Pharma

ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including atopic dermatitis (AD), vitiligo, inflammatory bowel disease, etc., with broad market prospects. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway and plays an important role in the pathogenesis of inflammatory diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Atopic Dermatitis.

APG777: Apogee Therapeutics

APG777 is a novel, subcutaneous half-life extended monoclonal antibody targeting IL-13 for the potential treatment of AD. In head-to-head preclinical studies, APG777 showed equivalent or better potency to lebrikizumab in the inhibition of IL-13 signaling. APG777 Phase 1 trial data out to 12 months demonstrated a half-life of 77 days, a consistent safety and favorable PD profile showing near complete inhibition of pSTAT6 for up to 12 months after a single administration and sustained TARC inhibition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

Barzolvolimab: Celldex Therapeutics

Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

ATI-2138: Aclaris Therapeutics

ATI-2138 is an investigational oral covalent inhibitor of ITK, and JAK3 for the potential treatment of T cell-mediated autoimmune diseases. The ITK/JAK3 compound interrupts T cell signaling through the combined inhibition of ITK/JAK3 pathways in lymphocytes. Aclaris is developing ATI-2138 as a potential treatment for T cell-mediated autoimmune diseases. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

STAR-0310: Astria Therapeutics

STAR-0310 is a monoclonal antibody designed as an OX40 antagonist, currently in preclinical development by Astria Therapeutics for the treatment of atopic dermatitis (AD) and potentially other immunologic conditions. Its mechanism of action involves inhibiting the OX40 receptor, which plays a critical role in T cell activation and survival, thereby modulating immune responses associated with AD. STAR-0310 is characterized by its high affinity and potency, coupled with a significantly reduced antibody-dependent cellular cytotoxicity (ADCC), which may lead to a more favorable safety profile and a broader therapeutic window compared to existing therapies. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Atopic Dermatitis.

If you’re tracking ongoing Atopic Dermatitis Clinical trials, this press release is a must-read @ Atopic Dermatitis Treatment Drugs

The Atopic Dermatitis Pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
Atopic Dermatitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.

Atopic Dermatitis Companies

Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.

Atopic Dermatitis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Atopic Dermatitis Products have been categorized under various Molecule types such as,

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

From emerging drug candidates to competitive intelligence, the Atopic Dermatitis Pipeline Report covers it all @ Atopic Dermatitis Market Drivers and Barriers, and Future Perspectives

Scope of the Atopic Dermatitis Pipeline Report

Coverage- Global
Atopic Dermatitis Companies- Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.
Atopic Dermatitis Therapies- Dupilumab, betamethasone valerate, GW842470X cream, LAS 41002, Hydrocortisone Ointment, Clobetasol Ointment, TAVO101, Apremilast, HY209GEL, and others.
Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Atopic Dermatitis Treatment landscape in this detailed analysis @ Atopic Dermatitis Emerging Drugs and Major Players

Table of Contents

Introduction
Executive Summary
Atopic Dermatitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Atopic Dermatitis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
ICP-332: Innocare Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
APG777: Apogee Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
STAR-0310: Astria Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Atopic Dermatitis Key Companies
Atopic Dermatitis Key Products
Atopic Dermatitis- Unmet Needs
Atopic Dermatitis- Market Drivers and Barriers
Atopic Dermatitis- Future Perspectives and Conclusion
Atopic Dermatitis Analyst Views
Atopic Dermatitis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atopic Dermatitis Pipeline Shows Potential with Active Contributions from 100+ Key Companies | DelveInsight

Author Kris Land Discusses Fear, Self-Awareness, and Personal Empowerment on the Anthony Guastella Wellness Podcast

Kris Land, award-winning author and serial entrepreneur behind The Infinity Within, was recently interviewed on the Anthony Guastella Wellness Podcast, where he shared a reflective and personal conversation about fear, self-awareness, spirituality, and the untapped potential within.

During the interview, Land discussed themes central to The Infinity Within, including the idea that fear is not simply an obstacle to avoid, but a signpost that can reveal where doubt, resistance, and conditioning are shaping a person’s life. Drawing from his own journey and the insights explored in his book, Land emphasized that fear often appears at moments of transformation and can become a powerful tool for personal growth when approached with awareness.

“Fear is not knowing,” Land shared during the conversation. He also described fear as “a signpost,” pointing listeners toward the inner doubts and limiting beliefs that may be keeping them from stepping fully into their potential.

The episode explores how early life experiences, societal expectations, and unconscious conditioning can teach people to remain small, compliant, or disconnected from their deeper sense of self. Land encourages listeners to become more aware of their body’s responses, question inherited beliefs, and recognize the power of self-belief in unlocking greater clarity, confidence, and empowerment.

Land’s audiobook, The Infinity Within, invites listeners into a contemplative journey through fear, awakening, and remembrance. Blending mysticism, lived experience, and grounded insight, the work unfolds through an intimate dialogue between a seeker and a teacher. Rather than offering a step-by-step formula, The Infinity Within creates space for reflection, inner knowing, and a different relationship with fear.

Narrated by acclaimed voice artist Edoardo Ballerini, known for transformational audiobook works such as The Power of Now and The Untethered Soul, The Infinity Within has been praised by Kirkus Reviews as “an intriguing and informative dialogue that persuasively makes the case that we’re infinite beings.”

In his interview with Anthony Guastella, Land also reflected on the meaning of coincidences, the exploration of the soul, and the importance of recognizing that personal empowerment begins by breaking free from limiting molds. The discussion offers listeners a thoughtful entry point into Land’s broader message: that awakening is less about becoming someone new and more about remembering what has always been within.

The Infinity Within is available now in paperback on Amazon and Barnes & Noble, and digitally on Kindle and Audible. Whether you prefer to read, listen, or reflect at your own pace, The Infinity Within invites you to discover a new relationship with fear, and remember who you truly are.

About the Author

Kris Land is a transformative, award-winning author and dynamic leader who has spent more than four decades mastering and simplifying complex fields, including construction, finance, technology, and spiritual development. His work is driven by a clear mission: to equip readers with practical tools, confidence, and clarity so they can reclaim power over their lives and shape their own destinies.

Kris first began documenting his owner-builder experience in the 2000s. Those early notes evolved into the acclaimed How to Build Your Dream Home series, a set of detailed, accessible manuals designed to help aspiring homebuilders save money, avoid setbacks, and build with confidence. He later expanded his impact into financial empowerment with The Finance Book for Young Adults, offering readers a foundational shift in how money works and how long-term wealth is built through actionable, real-world strategies.

Completed in 2025 after more than 40 years in the making, The Infinity Within is Kris’s most personal and profound work. Blending story-driven mysticism with lived insight, it invites readers to break through fear, trust their inner knowing, and remember the divine truth woven through their lives. Across every title, Kris delivers more than information. He offers transformation that helps readers build, grow, and awaken with purpose.

To learn more about Kris Land and explore his books, visit: KrisLand.com.

Media Contact
Company Name: Literary Titan
Contact Person: Kris Land
Email: Send Email
Country: United States
Website: https://krisland.com/

Mrs. Merriweather Mirrors: Reflections Of The Living Dead By Jackie Glanton Brings A Haunting Story Of Fear, Family, And Shadows

A voice in supernatural fiction beckons readers to experience the spine-chilling tale of childhood fears, family relationships, and hidden evil through Mrs. Merriweather Mirrors: Reflections of the Living Dead by Jackie Glanton.

Nita is a teenager whose quest for identity is disrupted when her family relocates from their previous residence to another suburban home in the South. As Nita tries to adjust to her new environment, her and her brother Ken’s curiosity leads them to discover an eerie old house located behind their backyard. The eeriness of the house can be felt through the eerie quietness and shadowy atmosphere that seems to be watching over them.

Combining themes of coming-of-age with those of supernatural fear, this book examines the nature of good and evil, the agony of feeling misunderstood, and the bravery required in order to confront the truth that others do not wish to face. Nita’s struggle is not just one of overcoming evil, but rather of maintaining her own strength in the face of fear.

Filled with an atmosphere of mystery, rich characterization, and family drama, Jackie Glanton’s Mrs. Merriweather Mirrors: Reflections of the Living Dead is sure to provide readers with a haunting tale filled with humanity and hope. The relationship between Nita and Ken provides both levity and a sense of comfort amidst the suspense.

The author infuses imagination, sincerity, and emotion into every page she writes. It is evident in her writing that she loves stories with deep meaning, secrets, and those which continue even after the last page.

For those who have a liking for ghostly mysteries, family suspense stories, and novels where the past does not die easily, this novel offers a paranormal experience with elements of fear, heart, mystery, and suspense.

Available now for readers worldwide through Amazon and other trusted book platforms: https://www.amazon.com/dp/B0H2GZJN8S

ABOUT THE AUTHOR:

Jackie Glanton is a generous and imaginative storyteller whose creativity shines through every page she writes. She openly celebrates the unconditional love she shares with her husband, her closest companion, and greatest joy. Known for her honesty, warmth, and unwavering trustworthiness, she finds inspiration in her circle of loved ones. When she is not writing, Jackie and her husband travel the world together, embracing new places, cultures, and experiences that continue to shape and inspire her work.

Book Name: Mrs. Merriweather Mirrors

Author Name: Jackie Glanton

ISBN Number: 979-8950388767

Paperback Version: Click Here

Kindle Version: Click Here

Hardcover Version: Click Here

Media Contact
Company Name: Stone Bridge Publishers
Email: Send Email
Phone: +1-708-286-8465
Address:Oak Park Business Center 1010 Lake Street
City: Oak Park
State: IL, 60301
Country: United States
Website: https://stonebridgepublishers.com/

Next Generation Immunotherapies Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight

Emerging Next Generation Immunotherapies therapies including OPDUALAG (relatlimab/nivolumab), Fianlimab (REGN-3767), Cobolimab (GSK-4069889), Tiragolumab (RG-6058), Ezabenlimab (BI-754091), and others are driving market size.

DelveInsight’s “Next Generation Immunotherapies Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Next Generation Immunotherapies, historical and forecasted epidemiology, as well as the Next Generation Immunotherapies market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Next Generation Immunotherapies Market with DelveInsight’s In-Depth Report @ Next Generation Immunotherapies Market Size

Key Takeaways from the Next Generation Immunotherapies Market Report

The leading Next Generation Immunotherapies companies include Bristol-Myers Squibb, Regeneron, Novartis, GlaxoSmithKline, Merck, Roche, AstraZeneca, and others.
Rising prevalence of cancer and autoimmune diseases globally is accelerating demand for advanced immunotherapies offering durable and targeted treatment outcomes.
Breakthroughs in CAR-T, TCR therapies, bispecific antibodies, and immune checkpoint modulators are expanding therapeutic applications and improving clinical efficacy.
The Next Generation Immunotherapies market in the 7MM is expected to witness major change during the study period 2020–2034.
Key targets currently under development include LAG-3, TIGIT, NKG2A, CD73, TIM-3, B7-H3, A2A receptor, FAK, CD47-SIRPα receptor, and CSF-1, among others.

Stay ahead in the Next Generation Immunotherapies Market with DelveInsight’s Strategic Report @ Next Generation Immunotherapies Market Outlook

Next Generation Immunotherapies Epidemiology Segmentation in the 7MM

Total Next Generation Immunotherapies Market Size
Market Size by Therapies
Market Size by Class
Next Generation Immunotherapies Treatment Market

Next Generation Immunotherapies Pipeline Analysis

OPDUALAG (relatlimab/nivolumab): Bristol-Myers Squibb OPDUALAG is a first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion. It is the first LAG-3 inhibitor granted FDA approval in March 2022 for the treatment of adult and pediatric patients aged 12 years or older with unresectable or metastatic melanoma.
Fianlimab (REGN-3767): Regeneron Pharmaceuticals Fianlimab is a fully human monoclonal antibody targeting the immune checkpoint receptor LAG-3 on T cells. In melanoma, LAG-3 expression on cancer cells is associated with therapeutic resistance to PD-1 inhibitors. It is being investigated in combination with Regeneron’s PD-1 inhibitor Libtayo to determine whether concurrent blockade of LAG-3 and PD-1 can help overcome resistance and enhance T-cell activation.
Cobolimab (GSK-4069889): GlaxoSmithKline Cobolimab is a monoclonal antibody targeting the inhibitory T-cell receptor TIM-3 (T-cell immunoglobulin and mucin domain-containing protein 3), with potential immune checkpoint inhibitory and antineoplastic activities.
Tiragolumab (RG-6058): Roche Tiragolumab is a novel immune checkpoint inhibitor with an intact Fc region that selectively binds to TIGIT, a novel inhibitory immune checkpoint that suppresses the immune response to cancer.
Ezabenlimab (BI-754091): Boehringer Ingelheim Ezabenlimab is a monoclonal antibody antagonist of the key myeloid cell checkpoint inhibitor SIRPα, preventing the SIRPα ligand CD47 from binding to SIRPα and thereby preserving the anti-tumorigenic properties of myeloid cells such as macrophages and dendritic cells.

Next Generation Immunotherapies Market Insights

The current treatment landscape includes checkpoint inhibitors, monoclonal antibody inhibitors, immune system modulators, vaccines, virus therapies, adoptive cell transfer, T-cell therapy, and targeted therapies.
Cancer immunotherapy is now considered the “fifth pillar” of cancer therapy, joining surgery, cytotoxic chemotherapy, radiation, and targeted therapy.
The competitive landscape is highly dynamic and innovation-driven, with leading players advancing CAR-T and CAR-NK cell therapies, bispecific and multispecific antibodies, immune checkpoint inhibitors, and cancer vaccines.
Strategic collaborations, licensing agreements, and mergers are common as companies seek to strengthen pipelines and access novel platforms.
The expected introduction of emerging therapies with improved efficacy, greater awareness initiatives, and further improvement in diagnosis rates are likely to boost market growth across the 7MM.

Get In-Depth Knowledge on Next Generation Immunotherapies Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/report-store/next-generation-immunotherapies-market

Next Generation Immunotherapies Market Outlook

Cancer immunotherapy harnesses the patient’s own immune system to fight cancer, distinguishing it from conventional therapies that directly target tumor cells. Immune checkpoints are pathways with inhibitory or stimulatory features that maintain self-tolerance and assist with immune response. Well-described checkpoints include CTLA-4, PD-1, and PD-L1. The Next Generation Immunotherapies pipeline is very robust, with many potential therapies under investigation, and the treatment space is expected to experience a significant market impact during the forecast period. Market growth may be offset by therapy failures or discontinuations, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Scope of the Next Generation Immunotherapies Market Report

Coverage: 7MM
Study Period: 2020–2034
Forecast Period: 2024–2034
Next Generation Immunotherapies Companies: Bristol-Myers Squibb, Regeneron, GlaxoSmithKline, Roche, Boehringer Ingelheim, and others
Next Generation Immunotherapies Therapies: OPDUALAG, Fianlimab, Cobolimab, Tiragolumab, Ezabenlimab, and others
Next Generation Immunotherapies Market Access & Reimbursements, Unmet Needs and Perspectives
Next Generation Immunotherapies SWOT Analysis and KOL Views

Unlock Strategic Insights with DelveInsight’s Comprehensive Next Generation Immunotherapies Market Report @ Next Generation Immunotherapies Market Drivers and Barriers

Table of Contents

1. Key Insights

2. Report Introduction

3. NGIs Market Overview at a Glance

3.1. Market Share (%) Distribution of NGIs in 2020: By Country

3.2. Market Share (%) Distribution of NGIs in 2034: By Country

3.3. Market Share (%) Distribution of NGIs in 2025: By Indication

3.4. Market Share (%) Distribution of NGIs in 2034: By Indication

4. Key Highlights from Report

5. Executive Summary of NGIs

5.1. Key Events

6. Epidemiology and Market Forecast Flow

7. Background and Overview

7.1. Introduction

7.2. Different types of NGIs

7.3. Applications of NGIs

7.4. Mechanisms of Action of NGIs for Cancer Therapy

7.5. Routes of Administration

7.5.1. Direct intratumoral delivery

7.5.2. IV delivery

7.5.3. Other routes of delivery

7.5.4. Comparing different administration routes

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Assumptions and Rationale

8.3. Epidemiology Scenario in the 7MM

8.3.1. Total Incident cases of target indications across the 7MM

8.3.2. Target Patient Pool of NGIs across the 7MM

8.3.3. Treated cases by line of therapy across the 7MM

8.4. Epidemiology Scenario in the US

8.4.1. Total Incident cases of target indications across the US

8.4.2. Target Patient Pool of NGIs across the US

8.4.3. Treated cases by line of therapy across the US

8.5. Epidemiology Scenario in EU5

8.5.1. Total Incident cases of target indications across EU5

8.5.2. Target Patient Pool of NGIs across EU5

8.5.3. Treated cases by line of therapy across EU5

8.6. Epidemiology Scenario in Japan

8.6.1. Total Incident cases of target indications across Japan

8.6.2. Indication wise target patient pool across Japan

8.6.3. Treated cases by line of therapy across Japan

9. Key Endpoints in NGIs

10. Marketed therapies

10.1. Key Cross of Marketed Therapies

10.2. OPDUALAG: Bristol Myers Squibb

10.2.1. Product description

10.2.2. Regulatory milestones

10.2.3. Other developmental activities

10.2.4. Pivotal clinical trial

10.2.5. Ongoing pipeline activity

11. Emerging Therapies

11.1. Key Cross Competition

11.2. Fianlimab (REGN-3767) : Regeneron Pharmaceuticals

11.2.1. Product description

11.2.2. Other developmental activities

11.2.3. Clinical development

11.2.4. Safety and efficacy

11.3. Tebotelimab (MGD013) : MacroGenics

11.3.1. Product description

11.3.2. Other developmental activities

11.3.3. Clinical development

11.3.4. Safety and efficacy

11.4. Ezabenlimab (BI-754091): Boehringer Ingelheim

11.4.1. Product description

11.4.2. Other developmental activities

11.4.3. Clinical development

11.4.4. Safety and efficacy

11.5. MGC 018 : MacroGenics

11.5.1. Product description

11.5.2. Other Developmental Activities

11.5.3. Clinical development

11.5.4. Safety and efficacy

11.6. Etigilimab : MereoBiopharma

11.6.1. Product description

11.6.2. Other developmental activities

11.6.3. Clinical development

11.6.4. Safety and efficacy

11.7. HB-0036 : Hubao Biopharm

11.7.1. Product description

11.7.2. Other developmental activities

11.7.3. Clinical development

11.7.4. Safety and efficacy

To be continued in the report…

12. Attribute Analysis

13. Next Generation Immunotherapies: 7 Major Market Analysis

13.1. Key Findings

13.2. Market Outlook

13.3. Market Size of NGIs in the 7MM

13.3.1. Total Market Size of NGIs

13.3.2. Total Market Size of NGIs by Indications in the 7MM

13.3.3. Market Size of NGIs by Therapies

13.4. Market Size of NGIs in the US

13.4.1. Total Market Size of NGIs

13.4.2. Total Market Size of NGIs by Indications

13.4.3. Market Size of NGIs by Therapies in the US

13.5. Market Size of NGIs in EU5

13.5.1. Total Market Size of NGIs

13.5.2. Total Market Size of NGIs by Indications

13.5.3. Market Size of NGIs by Therapies in EU5

13.6. Market Size of NGIs in Japan

13.6.1. Total Market Size of NGIs

13.6.2. Total Market Size of NGIs by Indications

13.6.3. Market Size of NGIs by Therapies in Japan

14. Market Access and Reimbursement

14.1. NICE UK

14.2. IQWiG and GBA Assessment

14.3. Japan

14.4. Patient assistance programs

15. KOL Views

16. SWOT Analysis

17. Unmet Needs

18. Appendix

18.1. Acronyms and Abbreviations

18.2. Bibliography

18.3. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

DelveInsight’s “Lymphocyte Activation Gene-3 (LAG-3) Competitive Landscape and Market Forecast – 2035” report delivers an in-depth understanding of the LAG-3, historical and forecasted market trends of LAG-3 in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Key LAG-3 Next-generation Immunotherapy companies working in the LAG-3 Next-generation Immunotherapy market are Bristol-Myers Squibb, Merck Sharp & Dohme Corp., MacroGenics, Immutep, Incyte Corporation, F-star Therapeutics, EpimAb Biotherapeutics, Roche, Xencor, AnaptysBio, GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi, Symphogen, and others.

ICOS-Next Generation Immunotherapy – Competitive Landscape and Market Forecast – 2035

DelveInsight’s ‘ICOS-Next Generation Immunotherapy Competitive Landscape and Market Forecast–2035’ report delivers an in-depth understanding of the ICOS as well as the ICOS-Next Generation Immunotherapy therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/next-generation-immunotherapies-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Next Generation Immunotherapies Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight

Alopecia Areata Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Alopecia Areata Pipeline Insight 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Alopecia Areata pipeline landscape. It covers the Alopecia Areata pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Alopecia Areata pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Alopecia Areata Pipeline @ https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight

Key Takeaways from the Alopecia Areata Pipeline Report

On June 01, 2026- Epibiotech initiated a Phase I/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of EPI-001 in patients with androgenetic alopecia. In the Phase I portion, a traditional 3+3 dose-escalation design will be used to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EPI-001. Subjects will be followed for up to 24 weeks after administration. In the Phase IIa portion, subjects will be randomized in a 2:1 ratio to receive either EPI-001 or placebo. Safety and efficacy will be evaluated through hair count assessment, hair diameter measurement, clinical photography, investigator assessment, expert panel assessment, and subject self-assessment during a follow-up period of up to 48 weeks.
On May 22, 2026- Eli Lilly and Company conducted a phase 2 study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it’s tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
On May 20, 2026- Almirall, S.A. announced a phase 2 study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.
DelveInsight’s Alopecia Areata pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Alopecia Areata treatment.
The leading Alopecia Areata Companies such as Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others.
Promising Alopecia Areata Pipeline Therapies such as PF-06651600, STS01, Upadacitinib, ADX-914, Etrasimod, Daxdilimab, CTP-543 and others.

Stay ahead with the most recent pipeline outlook for Alopecia Areata @ Alopecia Areata Treatment Drugs

Alopecia Areata Overview

Alopecia areata (AA) is a form of alopecia that impacts hair follicles, nails, and rarely, the retinal pigment epithelium. It typically presents with round patches and is a type of non-scarring hair loss. A significant feature of the hair follicle is its relative immune privilege, this mainly established by suppression of surface molecules required for presenting auto antigens to CD8+ T lymphocytes (i.e., MHC class I) and by the generation of an inhibitory local signaling environment. The breakdown of the immune privilege of the hair follicle has been thought to be a significant driver of AA.

Alopecia Areata Emerging Drugs

Deuruxolitinib: Concert Pharmaceuticals

Concert Pharmaceuticals is developing deuruxolitinib (CTP-543), an oral inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 breakthrough therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The company is evaluating the efficacy and safety of deuruxolitinib in adult patients with moderate to severe alopecia areata in its THRIVE-AA Phase III clinical program. Concert reported positive topline data from the clinical trials. Data from the clinical trials are intended to form the basis of a New Drug Application (NDA) planned to be submitted to the US Food and Drug Administration (FDA) by the first half of 2023.

EQ101: Equillium

EQ101 is a first-in-class, tri-specific inhibitor of IL-2, IL-9 and IL-15, three inflammatory cytokines implicated in multiple diseases. EQ101 was also shown to be well tolerated with a favorable safety profile with no drug-related SAEs and no dose-limiting toxicities. The drug is currently formulated for intravenous administration, with subcutaneous formulation development underway. It is currently in the Phase II stage of its development in alopecia areata, a dermatological autoimmune disorder.

MAX 40070: Maxinovel Pharmaceuticals

MAX-40070 is a topical JAK/Tyk2 inhibitor developed by Maxinovel. Preclinical studies have shown that topical administration of MAX-40070 could achieve an effective exposure in skin tissue while maintaining low systemic exposure. MAX-40070 has the potential to minimize the systemic side effects of oral JAK inhibitors and eventually demonstrates its high benefit/risk ratio through clinical trials, which may ultimately provide robust evidence to support its more broadly use in treating dermatological autoimmune disorders. Currently, the drug is in Phase I stage of its development for the treatment of Alopecia Areata.

The Alopecia Areata Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Alopecia Areata with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alopecia Areata Treatment.
Alopecia Areata Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Alopecia Areata Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alopecia Areata market

Explore groundbreaking therapies and clinical trials in the Alopecia Areata Pipeline @ New Alopecia Areata Drugs

Alopecia Areata Companies

Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others.

Alopecia Areata pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Alopecia Areata Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Alopecia Areata Market Drivers and Barriers

Scope of the Alopecia Areata Pipeline Report

Coverage- Global
Alopecia Areata Companies- Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited and others.
Alopecia Areata Pipeline Therapies- PF-06651600, STS01, Upadacitinib, ADX-914, Etrasimod, Daxdilimab, CTP-543 and others.
Alopecia Areata Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Alopecia Areata Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Alopecia Areata Therapies and clinical trials @ Alopecia Areata Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Alopecia Areata: Overview
Pipeline Therapeutics
Therapeutic Assessment
Alopecia Areata– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Deuruxolitinib: Concert Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
EQ101: Equillium
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
MAX 40070: Maxinovel Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Alopecia Areata Key Companies
Alopecia Areata Key Products
Alopecia Areata- Unmet Needs
Alopecia Areata- Market Drivers and Barriers
Alopecia Areata- Future Perspectives and Conclusion
Alopecia Areata Analyst Views
Alopecia Areata Key Companies
Appendix

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/alopecia-areata-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/alopecia-areata-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alopecia Areata Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Corey Hunt Launches Skilled Trades Commitment Pledge

Corey Hunt Lewiston

Lewiston, Maine electrician Corey Hunt announces a personal pledge to strengthen trades awareness, discipline, and workforce development across his community.

Lewiston, Maine – Master Electrician and Rocky Coast Electric owner Corey Hunt is launching a new personal initiative focused on rebuilding respect for skilled trades and strengthening workforce discipline in Maine.

After more than a decade in the electrical field — from solar installs in Massachusetts to union work across the United States — Hunt says the trades shortage is no longer a distant concern. It is visible on job sites every day.

“There’s more work than people think,” Corey Hunt says. “Most kids just aren’t shown the path.”

He believes the issue is not opportunity. It is awareness and exposure.

“I was just looking for guidance,” he says. “The trades gave me direction.”

Hunt’s pledge centers on structured training, mentorship, and personal accountability — values that shaped his own path from helper to Master Electrician.

“You don’t guess in this trade,” he says. “You either know it or you don’t.”

Why This Matters Now

The skilled trades workforce faces measurable strain:

The U.S. is projected to face a shortage of hundreds of thousands of electricians over the next decade.
Maine has one of the oldest workforces in the country, with many licensed trades professionals nearing retirement.
Demand for electricians is rising due to solar expansion and electric vehicle charging infrastructure growth.
The Bureau of Labor Statistics projects steady growth in electrical occupations through the coming years.

“The grid is changing,” Hunt says. “Electricians have to stay ahead.”

He believes Maine must act before the labor gap widens further.

The Corey Hunt Skilled Trades Commitment Pledge

Corey Hunt is committing to the following seven personal actions:

Host quarterly job-site observation days for high school students and young adults interested in electrical work.
Mentor at least one apprentice annually, providing structured guidance on licensing requirements and work discipline.
Partner with a local technical school to speak about real-world expectations in the trades.
Offer structured internship opportunities when business capacity allows.
Promote safety-first standards publicly, reinforcing licensing and code compliance education.
Commit to continuing education annually in solar, EV infrastructure, and evolving electrical standards.
Encourage faith, family, and responsibility conversations when mentoring younger workers.

“If you want responsibility, you have to prove you can handle it,” Hunt says. “You still have to climb it one step at a time.”

His pledge emphasizes skill before status.

“You don’t rush growth,” he says. “You build skill first.”

Do-It-Yourself Toolkit: 10 Actions Anyone Can Take

This initiative does not require policy change or financial contributions. Hunt encourages individuals to act independently.

Parents can:

Visit a local technical school with their teen.
Encourage hands-on summer work.
Discuss apprenticeship paths as seriously as four-year colleges.

Young adults can: 4. Research Maine licensing requirements online. 5. Contact a local electrical company about shadowing opportunities. 6. Attend a local career fair focused on skilled trades.

Community members can: 7. Promote trades careers on social media. 8. Invite trades professionals to speak at schools. 9. Respect and recommend licensed professionals. 10. Learn basic home electrical safety practices.

“In this business, integrity matters,” Hunt says. “Anybody can wire something. Not everyone stands behind it.”

30-Day Progress Tracker

Hunt encourages participants to commit for 30 days.

Week 1 ☐ Research local apprenticeship programs ☐ Identify one trades career of interest

Week 2 ☐ Speak with one licensed trades professional ☐ Review local technical school options

Week 3 ☐ Attend or plan to attend a career fair ☐ Learn one new electrical safety standard

Week 4 ☐ Share trades information with one family member ☐ Identify next step (application, shadowing, training inquiry)

Consistency builds awareness. Awareness builds workforce strength.

Call to Action

Corey Hunt invites Maine residents to take the Skilled Trades Commitment Pledge this month.

Visit a local technical school. Speak to a licensed electrician. Share this toolkit with a family member.

Trades careers build homes, infrastructure, and energy systems. They also build families and local businesses.

“The path is there,” Hunt says. “You just have to take the first step.”

About Corey Hunt

Corey Hunt is a Master Electrician based in Lewiston, Maine, and the owner of Rocky Coast Electric. He began his career in solar installations before earning his Master Electrician license and working with IBEW locals across the United States. In 2023, he founded Rocky Coast Electric, providing residential, commercial, solar, and EV electrical services. Hunt is committed to disciplined craftsmanship, faith, family, and strengthening the skilled trades workforce in Maine.

Contact Information

Email: coreyhunt@emaildn.com

Media Contact
Company Name: Corey Hunt Lewiston
Contact Person: Corey Hunt Lewiston
Email: Send Email
Country: United States
Website: https://www.corey-hunt.com/

360WiSE® Deploys the Neutral External Credibility Infrastructure Layer: Public Registry, Hash-Verified Specifications, and Machine-Readable Governance Now Live

“The framework does not ask to be trusted. It asks to be checked.” — Robert W. Alexander III, Founder & CEO, 360WiSE®

360WiSE® announced full deployment of its External Credibility Infrastructure Layer: entity verification against a published criteria specification (CIS-1.0), canonical machine-readable records in a public registry, and structured distribution through MassMediaHub™. The deployment includes hash-verified whitepapers, a reproducible SHA-256 provenance anchor, and open crawl access for AI systems. The Founding 100 cohort is open at 360wise.com/verify.

MIAMI – June 4, 2026 – 360WiSE® today announced the full deployment of its External Credibility Infrastructure Layer — a neutral framework that verifies entities against a published criteria specification, publishes canonical machine-readable records in a public registry, and structures those records in open standards that external systems are independently designed to ingest.

A neutral external credibility infrastructure layer operates outside of any single platform, application, or AI model. It does not generate content and does not execute core business logic. It exists to resolve three failure modes in modern information systems: identity continuity, authority verification, and provenance clarity. The verifier is 360WiSE®. The recognizer may be anyone.

One verb per layer

The architecture enforces a strict role boundary:

360WiSE® verifies. Entities are reviewed against the published criteria specification (CIS-1.0).
The 360WiSE® Registry publishes. Each verified entity receives a permanent, resolvable, machine-readable canonical record.
MassMediaHub™ distributes. The distribution layer carries verified records and content across owned media surfaces.
External systems recognize — independently. Recognition is observed and dated, never promised. 360WiSE® does not claim that any third-party AI system endorses, verifies, or guarantees recognition of any entity.

Machine-readable by design

The deployment includes the public governance record (Institutional Framework, Governance and Ethics, Signal Definitions, and the AI Provenance Record, anchored by a reproducible SHA-256 canonical declaration), four hash-verified whitepapers whose SHA-256 checksums are published for independent reproduction, and open crawl access for AI and search systems, declared by name at 360wise.com/robots.txt and documented for large language models at 360wise.com/llms.txt.

“Credibility has to be verifiable by anyone, including a machine, or it is just a claim,” said Robert W. Alexander III, Founder and CEO of 360WiSE®. “We publish the criteria, we publish the records, we publish the hashes. The framework does not ask to be trusted. It asks to be checked.”

The framework reflects capabilities, systems, and operating experience accumulated since 2014, and is structured on external open standards — Schema.org and JSON-LD, with alignment in principle to C2PA and W3C Verifiable Credentials. 360WiSE® publishes its own criteria as a specification, not an industry standard.

Independent machine observation

As of June 2026, independent AI search surfaces have been observed, on dated record, describing the external credibility infrastructure category and citing 360WiSE® materials, including the SiUtility™ layer, in response to public queries. 360WiSE® documents these observations as dated records. They are reproducible by anyone and are not presented as endorsement by any third-party system.

The Founding 100 Cohort

Enrollment is open for the Founding 100 — a non-renewable cohort of one hundred founding entities, each carrying a permanent numbered designation (№001–№100) in the registry’s foundational record. Founding entry is $199 per year. Verification pathways for individuals, professionals, institutions, and enterprise systems are documented at 360wise.com/verify.

Identity and trademark record

360WiSE® — USPTO Reg. №4968200 (Serial 86763393, IC 035); WIPO Madrid Protocol International Reg. №1553140 (United States, European Union, OAPI). Filed marks (USPTO Class 42, applications pending): AI Authority Infrastructure™ (Serial 99604888), AI Authority Stack™ (99604591), AI Authority Index™ (99605773), Credibility Infrastructure™ (99605278), and SiUtility™ (99773553). Independently verifiable via USPTO TSDR and the WIPO Global Brand Database.

About 360WiSE®

360WiSE® is the neutral External Credibility Infrastructure Layer — entity verification, canonical machine-readable records, and structured distribution. Established 2014. Headquartered at 1200 Brickell Ave, Ste 1950 #1211, Miami, FL 33131. Canonical documentation: 360wise.com.

About MassMediaHub™

MassMediaHub™ — written as one word, always — is the distribution layer of the 360WiSE® architecture: a creator-owned media and streaming network operated under the same founder, at massmediahub.com. MassMediaHub™ is not affiliated with Mediahub Worldwide, the IPG Mediabrands advertising agency; these are unrelated entities.

Contact

Robert W. Alexander III, Founder and CEO Robert@360Wise.com · 844-360-WISE 360wise.com · 360wise.com/verify

Media Contact
Company Name: 360Wise Media
Contact Person: Editorial Dept
Email: Send Email
Phone: 1-844-360-WiSE (9473)
Address:1200 Brickell Ave suite 1950
City: Miami
State: Fl
Country: United States
Website: https://360wise.com

Diabetic Neuropathic Pain Market is Projected to Grow Significantly by 2034 Owing to the Launch of Emerging Therapies | DelveInsight

The market dynamics for Diabetic Neuropathic Pain are witnessing steady growth driven by the rising prevalence of diabetes, increasing burden of neuropathic complications, growing demand for effective symptomatic therapies, and advancements in pain management approaches. Additionally, the launch of emerging therapies such as Suzetrigine (Vertex Pharmaceuticals), Pilavapadin/LX9211 (Lexicon Pharmaceuticals), and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Diabetic Neuropathic Pain Market Insights, Epidemiology, and Market Forecast 2034.” This comprehensive report provides an in-depth understanding of Diabetic Neuropathic Pain, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Diabetic Neuropathic Pain Market

The market size for Diabetic Neuropathic Pain in the 7MM is expected to increase significantly during the forecast period from 2020–2034.
The United States accounted for the highest Diabetic Neuropathic Pain market size in 2024 among the 7MM.
According to the International Diabetes Federation, nearly 425 million people worldwide have diabetes.
Diabetic neuropathy is the most common complication of diabetes mellitus, affecting as many as 50% of patients with Type 1 and Type 2 diabetes mellitus.
According to Feldman et al. (2019), approximately 30–50% of patients with diabetic neuropathy develop neuropathic pain.
The prevalence of diabetic neuropathy, including pain, tends to increase with age and longer diabetes duration.
Leading Diabetic Neuropathic Pain companies, such as Vertex Pharmaceuticals, Lexicon Pharmaceuticals, Bristol-Myers Squibb, Grünenthal (Averitas Pharma), Collegium Pharmaceuticals, and others, are developing novel treatment approaches to improve pain management outcomes.
The promising Diabetic Neuropathic Pain therapies in clinical trials include Suzetrigine (VX-548), Pilavapadin/LX9211, and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/diabetic-neuropathic-pain-dnp-market

Key Factors Driving the Diabetic Neuropathic Pain Market

Rising Prevalence of Diabetes and Associated Neuropathic Complications:The growing global burden of Type 1 and Type 2 diabetes is contributing significantly to the rise in diabetic neuropathy and neuropathic pain cases. Increasing obesity rates and aging populations are expected to further increase disease burden.
Increasing Demand for Effective Symptomatic Therapies:Current treatment approaches primarily focus on symptomatic pain management using anticonvulsants, antidepressants, opioids, and topical therapies. Drugs such as LYRICA (pregabalin), NUCYNTA ER (tapentadol), and QUTENZA (capsaicin) continue to play a major role in treatment practices.
Advancements in Emerging Non-opioid Pain Therapies:Companies are actively developing innovative therapies with novel mechanisms of action targeting pain signaling pathways. Emerging agents such as Suzetrigine and LX9211 are expected to improve efficacy and safety compared with currently available therapies.

Diabetic Neuropathic Pain Competitive Landscape

Several Diabetic Neuropathic Pain drugs in development include Suzetrigine (Vertex Pharmaceuticals), Pilavapadin/LX9211 (Lexicon Pharmaceuticals/Bristol-Myers Squibb), and others. These candidates target novel pathways involved in neuropathic pain signaling and are expected to provide improved symptomatic relief with fewer side effects.

Suzetrigine is an oral NaV1.8 inhibitor developed by Vertex Pharmaceuticals for the treatment of painful diabetic peripheral neuropathy. LX9211 is an orally administered small molecule developed by Lexicon Pharmaceuticals targeting adaptor-associated kinase 1 (AAK1) pathways involved in neuropathic pain modulation.

Discover more about therapies set to grab major Diabetic Neuropathic Pain market share @ Diabetic Neuropathic Pain Landscape

Recent Developments in the Diabetic Neuropathic Pain Market

In April 2024, Vertex Pharmaceuticals announced the successful completion of an end-of-Phase II meeting with the US FDA for Suzetrigine following positive Phase II results. The company initiated a Phase III pivotal trial in patients with painful DPN.
In June 2024, Lexicon Pharmaceuticals published research findings from its Phase II RELIEF-DPN-1 trial investigating LX9211 for DPN pain.
In October 2024, Lexicon Pharmaceuticals completed screening for the PROGRESS trial evaluating LX9211 and updated the expected timeline for top-line data release.
In November 2024, Lexicon Pharmaceuticals completed enrollment for the multicenter Phase IIb PROGRESS trial evaluating LX9211 for the treatment of diabetic peripheral neuropathic pain.

What is Diabetic Neuropathic Pain?

Diabetic neuropathic pain is one of the most common complications associated with diabetes mellitus and significantly impacts patient quality of life. It is characterized by chronic nerve pain caused by prolonged hyperglycemia-induced nerve damage. Common symptoms include burning sensations, tingling, numbness, and sharp pain, particularly in the feet and lower extremities.

Currently, treatment remains entirely symptomatic, with no disease-modifying therapies available. Existing pharmacological approaches primarily include anticonvulsants, antidepressants, opioids, and topical agents aimed at pain reduction rather than reversal of nerve damage.

Diabetic Neuropathic Pain Epidemiology Segmentation

The Diabetic Neuropathic Pain epidemiology section provides insights into the historical and current patient pool and forecasted trends for the 7MM. The Diabetic Neuropathic Pain market report proffers epidemiological analysis for the study period 2020–2034 segmented into:

Total Prevalent Cases of Diabetes Mellitus
Total Prevalent Cases of Diabetic Neuropathy
Total Prevalent Cases of Diabetic Neuropathic Pain
Age-specific Diagnosed Prevalent Cases of Diabetic Neuropathic Pain
Gender-specific Diagnosed Prevalent Cases of Diabetic Neuropathic Pain
Total Treated Cases of Diabetic Neuropathic Pain

Scope of the Diabetic Neuropathic Pain Market Report

Therapeutic Assessment: Diabetic Neuropathic Pain current marketed and emerging therapies
Diabetic Neuropathic Pain Market Dynamics: Key Market Forecast Assumptions of Emerging
Diabetic europathic Pain Drugs and Market Outlook
Key Companies: Vertex Pharmaceuticals, Lexicon Pharmaceuticals, Bristol-Myers Squibb,Grünenthal (Averitas Pharma), Collegium Pharmaceuticals, and other
Key Therapies: Suzetrigine (VX-548), Pilavapadin/LX9211, QUTENZA, NUCYNTA ER, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Diabetic Neuropathic Pain Market Access and Reimbursement

To know more about Diabetic Neuropathic Pain companies working in the treatment market, visit @ Diabetic Neuropathic Pain Trials and Therapeutic Assessment

Table of Contents

Diabetic Neuropathic Pain Market Report Introduction
Executive Summary for Diabetic Neuropathic Pain
SWOT Analysis of Diabetic Neuropathic Pain
Diabetic Neuropathic Pain Patient Share (%) Overview at a Glance
Diabetic Neuropathic Pain Market Overview at a Glance
Diabetic Neuropathic Pain Background and Overview
Diabetic Neuropathic Pain Epidemiology and Patient Population
Country-Specific Patient Population of Diabetic Neuropathic Pain
Diabetic Neuropathic Pain Current Treatment and Medical Practices
Diabetic Neuropathic Pain Unmet Needs
Diabetic Neuropathic Pain Emerging Therapies
Diabetic Neuropathic Pain Market Outlook
Country-Wise Diabetic Neuropathic Pain Market Analysis (2020–2034)
Diabetic Neuropathic Pain Market Access and Reimbursement of Therapies
Diabetic Neuropathic Pain Market Drivers
Diabetic Neuropathic Pain Market Barriers
Diabetic Neuropathic Pain Appendix
Diabetic Neuropathic Pain Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Neuropathic Pain Market is Projected to Grow Significantly by 2034 Owing to the Launch of Emerging Therapies | DelveInsight

EGFR Inhibitors-induced Skin Disorders Market is Projected to Grow by 2036 Owing to the Rising Use of Targeted Cancer Therapies and Emerging Novel Treatment Approaches | DelveInsight

The market dynamics for EGFR Inhibitors-induced Skin Disorders are witnessing significant growth driven by the increasing use of EGFR inhibitors across multiple cancer indications, rising incidence of dermatologic toxicities associated with anti-EGFR therapies, and growing demand for effective supportive care management strategies. Additionally, the launch of emerging therapies such as LUT-014 (Lutris Pharma), HT-001 (Hoth Therapeutics), ATR-04 (Azitra), and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s EGFR Inhibitors-induced Skin Disorders Market Insight, Epidemiology, and Market Forecast—2036.” This comprehensive report provides an in-depth understanding of EGFR Inhibitors-induced Skin Disorders, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the EGFR Inhibitors-induced Skin Disorders Market

The market size for EGFR Inhibitors-induced Skin Disorders in the 7MM is expected to grow steadily by 2036.
The United States holds the largest patient share of EGFR Inhibitors-induced Skin Disorders among the 7MM in 2025.
Among EU4 and the UK, Germany accounted for the highest cases of EGFR Inhibitors-induced Skin Disorders in 2025, followed by France and Spain.
According to Amaris et al. (2020), about 50–90% of patients treated with EGFR inhibitors develop a follicular or acneiform rash, negatively impacting quality of life.
As per Guggina et al. (2017), cutaneous complications are the most frequent adverse effects of EGFR inhibitors, occurring in up to 90% of patients treated with cetuximab therapy.
Dermatologic toxicity of any grade occurs in most patients who receive anti-EGFR therapy, while approximately 10%–20% of patients experience Grade 3/4 toxicity.
The major therapies in development for EGFR Inhibitors-induced Skin Disorders include LUT-014 (Lutris Pharma), HT-001 (Hoth Therapeutics), ATR-04 (Azitra), and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/egfr-inhibitors-induced-skin-disorders-market

Key Factors Driving the EGFR Inhibitors-induced Skin Disorders Market

Increasing Use of EGFR-targeted Cancer Therapies:The growing utilization of EGFR inhibitors in cancers such as Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), pancreatic cancer, head and neck cancer, and breast cancer is significantly increasing the burden of treatment-associated skin toxicities.

High Disease Burden and Lack of Approved Therapies:Currently, there are no approved therapies specifically indicated for the treatment of EGFR inhibitor-related cutaneous toxicities. Existing management approaches mainly rely on off-label use of topical steroids, antibiotics, emollients, antihistamines, and systemic corticosteroids.

Growing Focus on Supportive Oncology Care:As anti-EGFR therapies continue to expand across multiple tumor types and treatment regimens, there is an increasing emphasis on proactive toxicity management to improve patient quality of life, treatment adherence, and continuation of anticancer therapies.

EGFR Inhibitors-induced Skin Disorders Competitive Landscape

Several EGFR Inhibitors-induced Skin Disorders therapies are currently under development, including LUT-014 (Lutris Pharma), HT-001 (Hoth Therapeutics), and ATR-04 (Azitra).

LUT-014 is a topical B-Raf inhibitor being evaluated for EGFR inhibitor-induced acneiform lesions. HT-001 is a topical formulation under investigation for mild-to-moderate rash and skin disorders associated with EGFR inhibitor therapy. ATR-04 is a live biotherapeutic product candidate developed to address EGFR inhibitor-associated skin toxicity through modulation of skin immunity and inflammation pathways.

Discover more about therapies set to grab major EGFR Inhibitors-induced Skin Disorders market share @ EGFR Inhibitors-induced Skin Disorders Treatment Landscape

Recent Developments in the EGFR Inhibitors-induced Skin Disorders Market

In August 2025, Azitra announced dosing of the first patient in its Phase I/II clinical trial evaluating ATR04-484 for EGFR-associated rash.
In July 2025, Lutris Pharma presented positive Phase II trial data demonstrating efficacy of LUT014 gel in treating acneiform rash associated with anti-EGFR cancer therapies at the ESMO Gastrointestinal Cancers Congress 2025.
In April 2025, Lutris Pharma presented new data from its clinical trial of LUT014 gel at the AACR Annual Meeting 2025.
In September 2025, Hoth Therapeutics announced submission of a clinical trial application to the European Medicines Agency to expand its ongoing Phase II trial of HT-001.
In June 2025, Hoth Therapeutics presented interim results from the Phase IIa CLEER-001 trial of HT-001 highlighting preservation of cancer treatment while resolving dermatologic side effects.
In May 2025, Azitra presented posters describing the Phase I/II clinical trial of ATR04-484 at both the American Society of Clinical Oncology Annual Meeting and the American Society of Gene and Cell Therapy Annual Meeting.

What are EGFR Inhibitors-induced Skin Disorders?

EGFR Inhibitors-induced Skin Disorders are dermatologic toxicities caused by therapies targeting the Epidermal Growth Factor Receptor (EGFR). Common manifestations include acneiform rash, xerosis, pruritus, eczema, paronychia, and hair abnormalities. These skin toxicities can significantly affect patient quality of life and often interfere with continuation of anticancer therapy.

Management strategies generally involve topical corticosteroids, antibiotics, moisturizers, antihistamines, and supportive care interventions. However, there remains a substantial unmet need for approved therapies specifically designed for EGFR inhibitor-induced skin disorders.

EGFR Inhibitors-induced Skin Disorders Epidemiology Segmentation

The EGFR Inhibitors-induced Skin Disorders epidemiology section provides insights into the historical and current patient pool and forecasted trends across the 7MM. The market report proffers epidemiological analysis for the study period 2022–2036 segmented into:

Incident Cases of Indications Harboring EGFR Mutation in the 7MM
Incident Cases of EGFR Mutation in Respective Indications in the 7MM
Incident Cases of Treatable Population by EGFR Inhibitors in the 7MM
Incident Cases of EGFR Inhibitor-induced Skin Disorders in the 7MM

Scope of the EGFR Inhibitors-induced Skin Disorders Market Report

Therapeutic Assessment: Current and emerging therapies for EGFR Inhibitors-induced Skin Disorders
EGFR Inhibitors-induced Skin Disorders Market Dynamics: Key Market Forecast Assumptions and Market Outlook
Key Companies: Lutris Pharma, Hoth Therapeutics, Azitra, and others
Key Therapies: LUT-014, HT-001, ATR-04, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

To know more about EGFR Inhibitors-induced Skin Disorders companies working in the treatment market, visit @ EGFR Inhibitors-induced Skin Disorders Clinical Trials and Therapeutic Assessment

Table of Contents

EGFR Inhibitors-induced Skin Disorders Market Report Introduction
Executive Summary of EGFR Inhibitors-induced Skin Disorders
Epidemiology and Market Methodology
EGFR Inhibitors-induced Skin Disorders Market Overview at a Glance
Disease Background and Overview
Epidemiology and Patient Population
Emerging Therapies
EGFR Inhibitors-induced Skin Disorders: 7MM Analysis
Market Outlook
Market Size by Therapies
Unmet Needs
SWOT Analysis
KOL Views
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EGFR Inhibitors-induced Skin Disorders Market is Projected to Grow by 2036 Owing to the Rising Use of Targeted Cancer Therapies and Emerging Novel Treatment Approaches | DelveInsight